BEAM Stock Risk & Deep Value Analysis
Beam Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About BEAM Stock
We analyzed Beam Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BEAM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
BEAM Risk Analysis & Red Flags
What Could Go Wrong
Despite a strong cash position, clinical trial failures for its lead candidates (e.g., risto-cel or BEAM-302) would severely devalue Beam's platform and could lead to a significant stock price decline, given the company is still pre-commercial and highly dependent on pipeline success.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
High R&D expenditure without commercialized products, leading to substantial negative operating cash flow ($128.5M in Q1 2026).
- ⚠
Reliance on collaboration revenues and milestones (e.g., $25M from Lilly in Q1) which can be lumpy and unpredictable.
- ⚠
Early-stage nature means high valuation is primarily based on future potential and not current earnings/revenue streams.
- ⚠
Competitive landscape in gene editing is intense, with several well-funded rivals developing alternative or similar technologies.
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for lead candidates
- 📅
Unexpected regulatory delays or challenges with the FDA
- 📅
Increased R&D spending outpacing milestone revenue, leading to accelerated cash burn
When to Reconsider
- 🚪
Exit if a Phase 1 or Phase 2 clinical trial for a key candidate (e.g., risto-cel, BEAM-302) fails or shows significant safety concerns.
- 🚪
Sell if cash balance drops below $500M without a clear path to profitability or new funding, indicating a shorter runway than expected.
- 🚪
Exit if a major competitor announces superior clinical results or gains significant regulatory advantage for a similar indication.
Unlock BEAM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Beam Therapeutics Inc (BEAM) Do?
Market Cap
$3.25B
Sector
Healthcare
Industry
Biotechnology
Employees
509
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit Beam Therapeutics Inc WebsiteInvestment Thesis
Beam Therapeutics is a leading innovator in gene editing, specifically base editing, poised to deliver precision genetic cures for a wide range of diseases. With a robust cash runway, strong revenue growth from collaborations, and multiple programs advancing through clinical trials, it is strategically positioned for potential market leadership in a transformative healthcare sector. The company's technology offers significant advantages over conventional gene-editing methods, making it a high-conviction play on future genomic medicine.
Is BEAM Stock Undervalued?
Unlock the full AI analysis for BEAM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
BEAM Price Targets & Strategy
12-Month Target
$55.00
Bull Case
$80.00
Bear Case
$25.00
Valuation Basis
Derived from analyst consensus median ($51.13) with an additional premium for recent strong Q1 2026 results and robust cash runway, implying continued pipeline execution and re-rating.
Entry Strategy
Dollar-cost average between $30-$35, targeting dips towards recent support levels. Consider initial smaller position, adding upon positive clinical data readouts.
Exit Strategy
Take 30-50% profit at $60-$75. Re-evaluate full position at $80+ based on significant clinical milestones. Stop loss set at $28 to manage downside if clinical news turns negative or funding issues arise.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate risk tolerance, given its high-risk, high-reward biotech profile.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is BEAM Financially Healthy?
Valuation
P/E Ratio
-5.16
Price/Book
2.39
Price/Sales
38.33
Profitability
Operating Margin
-226.58%
Net Margin
-39.66%
Return on Equity
-5.89%
Revenue Growth
157.97%
EPS
$-0.64
Balance Sheet
Current Ratio
13.09
Quick Ratio
12.85
Debt/Equity
0.16
Total Debt
$151.42M
Cash & Equivalents
$1.07B
Cash Flow
Operating Cash Flow
-$338.18M
Free Cash Flow
-$352.36M
Other
Beta (Volatility)
2.21
Does BEAM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is driven by Beam's intellectual property protecting its base editing platform. As clinical trials advance and validate the safety and efficacy of this technology, the IP becomes more valuable and difficult for competitors to circumvent. Durability depends on continued innovation and successful patent defense.
Moat Erosion Risks
- •Emergence of a superior or more cost-effective gene editing technology from a competitor.
- •Patent challenges or expirations that could erode IP protection.
- •Clinical trial failures that undermine the perceived efficacy or safety advantages of base editing.
BEAM Competitive Moat Analysis
Sign up to see competitive advantages
BEAM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, driven by excitement around innovative gene-editing technology and potential cures for severe genetic diseases.
Institutional Sentiment
Positive, with 17 analysts having a Mean BUY rating and a median price target of $51.13, indicating strong confidence in the company's long-term potential.
Insider Activity (Form 4)
No Form 4 insider buys/sells reported in the last 90 days (SEC filings).
Options Flow
Normal options activity, with no specific unusual institutional positioning flagged in recent data. General sentiment likely reflects underlying stock price action.
Earnings Intelligence
Next Earnings
Estimated August 2026 (Q2 2026)
Surprise Probability
Medium (Q1 2026 saw EPS beat, but collaboration revenues can be unpredictable quarter-to-quarter).
Historical Earnings Pattern
Stock price reaction to earnings can be volatile, heavily influenced by pipeline updates and cash runway visibility, rather than just revenue/EPS beats/misses in this early stage.
Key Metrics to Watch
Competitive Position
Top Competitor
CRSP (CRISPR Therapeutics)
Market Share Trend
Not applicable; pre-commercial stage. Focused on gaining initial market share post-approval.
Valuation vs Peers
Beam currently trades at a high price-to-sales (P/S) multiple similar to other early-stage, innovative gene-editing biotechs, reflecting significant future growth potential rather than current fundamentals. Its P/S of ~23x (FY25) is competitive within the sector given its advanced platform.
Competitive Advantages
- •Proprietary base editing technology offering greater precision and potentially fewer off-target effects than traditional CRISPR/Cas9 methods.
- •Diverse pipeline addressing a range of high-unmet-need genetic diseases.
- •Strategic partnerships (e.g., Eli Lilly) validate technology and provide funding/expertise.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive BEAM Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Estimated August 2026)
- •Presentations at RBC Global Healthcare Conference (May 2026) and EHA (May 2026) with potential new data for sickle cell therapy (risto-cel)
- •Updated Phase 1/2 biomarker data for sickle cell therapy (risto-cel)
Medium-Term (6-18 months)
- •Further clinical trial advancements for risto-cel (sickle cell) and BEAM-302 (alpha-1 antitrypsin deficiency)
- •Submission of Investigational New Drug (IND) application for BEAM-304 PKU program (Expected 2026)
- •Potential new strategic partnerships or expanded collaborations beyond existing ones
Long-Term (18+ months)
- •Regulatory filings and potential approval for lead programs (e.g., risto-cel) positioning Beam as a leader in gene editing therapies
- •Expansion of base editing platform to address a wider range of genetic diseases, establishing a broad therapeutic pipeline
- •Disruption of existing standard-of-care treatments for genetic disorders with superior, more precise gene editing
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for BEAM?
- ✓
Positive clinical trial data readouts (especially Phase 2 and 3 results for lead candidates)
- ✓
Regulatory milestones, such as IND approvals and Fast Track designations
- ✓
New or expanded collaboration agreements with major pharmaceutical companies
- ✓
Sustained reduction in net loss and improving cash burn rates
Bull Case Analysis
Sign up free to see the bull case
Competing with BEAM
See how Beam Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Beam Therapeutics Inc BEAM | $3.2B | 9.4 | -5.2 | $55.7M | -39.7% | 158.0% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Beam Therapeutics Inc Makes Money
Beam Therapeutics is an early-stage biotechnology company that designs and develops precision genetic medicines using its proprietary base editing technology. Unlike traditional gene editing that cuts DNA, base editing chemically modifies single DNA bases without causing double-stranded breaks, aiming for greater precision and fewer off-target effects. Beam currently generates revenue primarily through strategic collaborations and milestone payments from partnerships with larger pharmaceutical companies, leveraging its technology and pipeline programs. The company's goal is to develop and commercialize its own gene-editing therapies to treat serious genetic diseases, ultimately making money by bringing these innovative medicines to patients.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Beam Therapeutics Inc (BEAM)?
As of May 13, 2026, Beam Therapeutics Inc has a DVR Score of 9.4 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Beam Therapeutics Inc?
Beam Therapeutics Inc's market capitalization is approximately $3.2B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Beam Therapeutics Inc use?
BEAM is the ticker symbol for Beam Therapeutics Inc. The company trades on the NMS.
What is the risk level for BEAM stock?
Our analysis rates Beam Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of BEAM?
Beam Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -5.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Beam Therapeutics Inc's revenue growing?
Beam Therapeutics Inc has reported revenue growth of 158.0%. The company is showing strong top-line momentum.
Is BEAM stock profitable?
Beam Therapeutics Inc has a profit margin of -39.7%. The company is currently unprofitable.
How often is the BEAM DVR analysis updated?
Our AI-powered analysis of Beam Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 13, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BEAM (Beam Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.